ATTENSION DEFICIT/HYPERACTIVITY DISORDER (ADHD)- signs and symptoms, Diagnosis, latest management
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity and impulsivity. It affects millions of children, adults globally every year. ICD-11 guidelines state that ADHD onset begins before 12-years age and often persists in the adulthood. This is a review article which focuses mainly on ADHD symptoms and differentiates between child and adulthood symptoms. The 3 main symptoms of ADHD are inattentiveness, hyperactive-impulse symptoms and combined symptoms. Knowing the different symptoms in both the adults and children help in understanding the treatment options also. Managing ADHD is needed to improve the quality of life of effected patients, this article provides a brief therapeutic management and Simtriyo is the recently approved new drug for ADHD treatment in adults and pediatrics. This new drug approval helps to increase the treatment options. Although, not well-known , but the use of EndeavorRX, a video game for treating ADHD can also improve the symptoms. Managing ADHD: it includes both pharmacological and non-pharmacological treatments. Pharmacotherapy includes stimulants such as methylphenidate, amphetamines and non -stimulants such as atomoxetine, viloxazine, alpha-2 agonist (clonidine, guanfacine). Recently Centanafadine (Simtriyo) has been approved by FDA. Centanafadine is a norepinephrine, dopamine, serotonin reuptake inhibitors which helps in decreasing the symptoms. Non- pharmacological approaches are neurofeedback, dietary supplements, behavioral therapy.
Authors
- Anusha Rudroju
- Km Grace
- Keerthana Reddy Danam
Institutions
- G Pulla Reddy Dental College & Hospital (IN)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24414261
- Primary Topic
- Attention Deficit Hyperactivity Disorder
- Type
- article
- Field-Weighted Citation Impact
- 0.00